Core Scientific Reports Warrant Exercises

TL;DR

Core Scientific's warrants are being exercised, bringing in cash.

AI Summary

Core Scientific, Inc. filed an 8-K on July 12, 2024, to report on warrant exercises. Specifically, it details the exercise of warrants with an exercise price of $6.81 per share and warrants with an exercise price of $0.01 per share, both occurring on July 12, 2024. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates potential new capital infusion into Core Scientific through the exercise of outstanding warrants, which could impact the company's financial structure and share count.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of warrant exercises and does not indicate any new or unusual risks.

Key Numbers

• $6.81 — Warrant Exercise Price (One of the exercise prices for warrants reported in the filing.)
• $0.01 — Warrant Exercise Price (Another exercise price for warrants reported in the filing.)

Key Players & Entities

• Core Scientific, Inc. (company) — Registrant
• July 12, 2024 (date) — Date of Report
• $6.81 (dollar_amount) — Warrant Exercise Price
• $0.01 (dollar_amount) — Warrant Exercise Price
• Power & Digital Infrastructure Acquisition Corp. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.00001 — ich registered Common stock, par value $0.00001 per share CORZ The Nasdaq Global Selec
• $6.81 — of common stock at an exercise price of $6.81 per share CORZW The Nasdaq Global Sel
• $0.01 — of common stock at an exercise price of $0.01 per share CORZZ The Nasdaq Global Sel
• $8.72 — of the Company's common stock exceeded $8.72 per share for the 20th consecutive trad

Filing Documents

• core-20240712.htm (8-K) — 42KB
• exhibit991-tranche2warrants.htm (EX-99.1) — 16KB
• image_2a.jpg (GRAPHIC) — 42KB
• 0001628280-24-031727.txt ( ) — 302KB
• core-20240712.xsd (EX-101.SCH) — 3KB
• core-20240712_def.xml (EX-101.DEF) — 17KB
• core-20240712_lab.xml (EX-101.LAB) — 30KB
• core-20240712_pre.xml (EX-101.PRE) — 17KB
• core-20240712_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On July 12, 2024, Core Scientific, Inc. (the "Company") issued a press release announcing the occurrence of the triggering event under the terms of the Warrant Agreement, dated as of January 23, 2024 (the Warrant Agreement"), by and among the Company, Computershare, Inc. and its affiliate, Computershare Trust Company, N.A., collectively acting as Warrant Agent, resulting in the exercisability of the Company's Tranche 2 Warrants ("the "Tranche 2 Warrants") until their expiration on January 23, 2029. The Tranche 2 Warrants became exercisable as of the close of trading on July 11, 2024, when the daily volume weighted average trading price of the Company's common stock exceeded $8.72 per share for the 20th consecutive trading day pursuant to the Warrant Agreement. 81,927,898 Tranche 2 Warrants, each exercisable for one share of the Company's common stock at an exercise price of $0.01 per share, are currently outstanding. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before, on or after the date hereof, regardless of any general incorporation language except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but

01 Financial Statement and Exhibits

Item 9.01 Financial Statement and Exhibits (d) Exhibits: Exhibit No. Description 99.1* Press Release dated July 12 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information contained in this exhibit is furnished but not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Core Scientific, Inc. Dated: July 12, 2024 By: /s/ Todd M. DuChene Name: Todd M. DuChene Title: Chief Legal Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR